TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10764156

Group type: EXPERIMENTAL
Intervention: Protocol VII (1988-1991)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Protocol VIII (1991-1997)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Protocol VI (1984-1988)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Post-induction/post-re-induction
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Post-CNS treatment
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Post-maintenance
Number of subjects: 46
Study: 8616736

Group type: EXPERIMENTAL
Intervention: Screening mammography prescribed by family physicians
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Previous mammograms
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Physician's prescription belief
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Fear of mammography
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Lack of time to take the test
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 171
Study: 1470390

Group type: EXPERIMENTAL
Intervention: Type 2 plaques (intermediate, partially echogenic)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Type 3 plaques (highly echogenic)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Type 1 plaques (non echogenic)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: MR scanning
Number of subjects: 300
Study: 6237662

Group type: EXPERIMENTAL
Intervention: Halothane via face mask
Number of subjects: 120

Group type: COMPARATOR
Intervention: Neuromuscular blocking drugs with controlled ventilation
Number of subjects: 120
Study: 30075523

Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 175

Group type: COMPARATOR
Intervention: Sufentanil
Number of subjects: 175
Study: 27755490

Group type: EXPERIMENTAL
Intervention: Morphine5 (5 mg morphine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine10 (10 mg morphine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine15 (15 mg morphine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine5
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine10
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Morphine15
Number of subjects: 90
Study: 24161321

Group type: EXPERIMENTAL
Intervention: Short dual antiplatelet therapy (DAPT) regimen (6 months)
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: Long dual antiplatelet therapy (DAPT) regimen (24 months)
Number of subjects: 224

Group type: COMPARATOR
Intervention: Short and long dual antiplatelet therapy (DAPT) regimens
Number of subjects: 224
Study: 23529568

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 808

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 808

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 808
Study: 20051370

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Genetic deletion of COX1 or COX2
Number of subjects: 60
Study: 18624836

Group type: EXPERIMENTAL
Intervention: MAL‐PDT (two sessions, 7 days apart, repeated 3 months later if incomplete clinical response)
Number of subjects: 196

Group type: COMPARATOR
Intervention: Surgery (at baseline)
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: MAL‐PDT
Number of subjects: 196

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 196
Study: 16617757

Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.125% with 1 microg/ml fentanyl
Number of subjects: 63

Group type: COMPARATOR
Intervention: Bupivacaine 0.125% with 1 microg/ml fentanyl
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Institutional clinical practice
Number of subjects: 63
Study: 12379291

Group type: EXPERIMENTAL
Intervention: Uniplas
Number of subjects: 84

Group type: COMPARATOR
Intervention: Octaplas
Number of subjects: 84
Study: 10909468

Group type: EXPERIMENTAL
Intervention: Cytokine production by PBMC stimulated with mitogens for 48 hours
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: TNF alpha and TNF beta production
Number of subjects: 114

Group type: COMPARATOR
Intervention: Intracellular expression of cytokines in CD4+ lymphocytes
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Serum level of IgG and production of TNF alpha, TNF beta, and IL-10 by PBMCs
Number of subjects: 114
Study: 7743569

Group type: EXPERIMENTAL
Intervention: Midazolam 75 micrograms.kg‐1 iv after induction of anaesthesia
Number of subjects: 215

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 215
Study: 2149514

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 30
Study: 7030578

Group type: EXPERIMENTAL
Intervention: Lofexidine (0.2 to 1.6 mg/day)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clonidine (0.2 to 1.6 mg/day)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Lofexidine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Clonidine
Number of subjects: 28
Study: 31935783

Group type: EXPERIMENTAL
Intervention: nrTMS with priming stimulation
Number of subjects: 12

Group type: COMPARATOR
Intervention: nrTMS without priming stimulation
Number of subjects: 12
Study: 30835093

Group type: EXPERIMENTAL
Intervention: Self-Management of Dietary Intake Using Mindful Eating intervention for 6 weeks
Number of subjects: 19
Study: 28562733

Group type: EXPERIMENTAL
Intervention: Local infiltration (0.75% ropivacaine) under general anesthesia
Number of subjects: 40

Group type: COMPARATOR
Intervention: Subarachnoid block (2 ml of 0.5% bupivacaine)
Number of subjects: 40
Study: 25904073

Group type: EXPERIMENTAL
Intervention: Antihypertensive therapy prescribed at ED discharge
Number of subjects: 217

Group type: COMPARATOR
Intervention: No antihypertensive therapy prescribed
Number of subjects: 217
Study: 24152240

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg (30 mg for 1 week, then 60 mg for 5 weeks)
Number of subjects: 239

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239

Group type: EXPERIMENTAL
Intervention: Duloxetine
Number of subjects: 239
Study: 22936078

Group type: EXPERIMENTAL
Intervention: Providing emotional support to mother during illness
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Receiving emotional support during mother's illness
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Providing emotional support to mother diagnosed with cancer no more than 5 years previously
Number of subjects: 147
Study: 19668928

Group type: EXPERIMENTAL
Intervention: Multiple micronutrients (MM) supplementation (daily, 6 days/week)
Number of subjects: 507

Group type: COMPARATOR
Intervention: Iron only (Fe) supplementation (daily, 6 days/week)
Number of subjects: 507
Study: 17615064

Group type: EXPERIMENTAL
Intervention: Nutrition supplementation (50 g/day of micronutrient fortified foods)
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Physical exercise intervention
Number of subjects: 2800

Group type: EXPERIMENTAL
Intervention: Nutrition supplementation and physical exercise intervention
Number of subjects: 2800
Study: 15106797

Group type: EXPERIMENTAL
Intervention: 8 g/day of water-soluble fiber from oat bran
Number of subjects: 110
Study: 11290876

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 11783254

Group type: EXPERIMENTAL
Intervention: Fuzheng Yiai Decoction (FZYAD) combined with chemotherapy
Number of subjects: 68

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 68
Study: 7540460

Group type: EXPERIMENTAL
Intervention: MACOP-B
Number of subjects: 286

Group type: COMPARATOR
Intervention: F-MACHOP
Number of subjects: 286
Study: 2318222

Group type: COMPARATOR
Intervention: Enalapril (10 mg b.i.d.)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Felodipine (10 mg b.i.d.)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between Felodipine and Enalapril
Number of subjects: 20
Study: 368368

Group type: EXPERIMENTAL
Intervention: Carbuterol hydrochloride 2 mg, three times daily
Number of subjects: 12

Group type: COMPARATOR
Intervention: Ephedrine sulfate 25 mg, three times daily
Number of subjects: 12
Study: 31550363

Group type: EXPERIMENTAL
Intervention: REAL-B score (derived from 7 variables: male gender, age, alcohol use, diabetes, baseline cirrhosis, platelet count, and AFP)
Number of subjects: 8048
Study: 29228822

Group type: EXPERIMENTAL
Intervention: Herbal combination capsule (600 mg) containing Terminalia chebula (200 mg), Commiphora mukul (200 mg), Commiphora myrrha (200 mg) taken 3 times a day for 3 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo capsule (600 mg toast powder) taken 3 times a day for 3 months
Number of subjects: 0
Study: 26482687

Group type: EXPERIMENTAL
Intervention: CoQ10 and organic selenium yeast combined
Number of subjects: 443

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 443
Study: 23943825

Group type: EXPERIMENTAL
Intervention: Baseline CD4(+) <50 cells/µL
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Greater relative 16-week increase in CD4(+) count
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: Older age, female sex, lower BMI, higher HIV-1 RNA levels, PI and tenofovir assignment
Number of subjects: 796

Group type: EXPERIMENTAL
Intervention: ART initiation at higher CD4(+) counts
Number of subjects: 796
Study: 20835732

Group type: EXPERIMENTAL
Intervention: Greater omental flap (OF group)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (non-OF group)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Patients with DGE
Number of subjects: 40
Study: 19052855

Group type: EXPERIMENTAL
Intervention: Tomato extract
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 17202200

Group type: EXPERIMENTAL
Intervention: 25-gauge system
Number of subjects: 60

Group type: COMPARATOR
Intervention: 20-gauge system
Number of subjects: 60
Study: 12787964

Group type: EXPERIMENTAL
Intervention: Glucosol (32mg daily for 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucosol (48mg daily for 2 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Glucosol (soft gel capsule formulation)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Glucosol (dry‐powder filled hard gelatin capsule formulation)
Number of subjects: 0
Study: 10826401

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil (8 to 16 mg)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Enalapril (10 to 20 mg)
Number of subjects: 429

Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) (12.5 to 25 mg)
Number of subjects: 429
Study: 8648531

Group type: EXPERIMENTAL
Intervention: Continuous feeding (24-hour nasogastric feedings)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intermittent feeding (every 3 hours nasogastric feedings)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Continuous feeding (n = 17 male neonates)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Intermittent feeding (n = 13 male neonates)
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Continuous feeding
Number of subjects: 82
Study: 1735869

Group type: EXPERIMENTAL
Intervention: Wearing headphones and listening to music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Wearing headphones but hearing no music
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group, not wearing headphones
Number of subjects: 60
Study: 6397541

Group type: EXPERIMENTAL
Intervention: Behaviourally-oriented weight loss ('diet') programme administered by professional dietitians
Number of subjects: 60

Group type: COMPARATOR
Intervention: No-treatment control group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Behaviourally-oriented weight loss ('diet') programme
Number of subjects: 60
Study: 3537101

Group type: EXPERIMENTAL
Intervention: Sodium ipodate (1 g daily for 10 days)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saturated solution of potassium iodide (SSKI, 12 drops daily for 10 days)
Number of subjects: 0
Study: 29159529

Group type: EXPERIMENTAL
Intervention: Sevelamer (SEV)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study: 27331354

Group type: EXPERIMENTAL
Intervention: LED light centered at 497 nm (turquoise)
Number of subjects: 83

Group type: COMPARATOR
Intervention: LED light centered at 459 nm (blue)
Number of subjects: 83
Study: 25031274

Group type: EXPERIMENTAL
Intervention: Erlotinib (100mg) plus WBRT (20 Gy in 5 fractions) followed by maintenance erlotinib (150 mg)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo plus WBRT (20 Gy in 5 fractions) followed by maintenance placebo
Number of subjects: 80
Study: 22414522

Group type: EXPERIMENTAL
Intervention: Hydrofluoric acid 10% (HF) + silane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: CoJet + silane
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HF + Metal/Zirconia Primer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HF + Clearfil Primer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HF + Alloy Primer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: HF + V‐Primer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metal/Zirconia Primer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clearfil Primer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Alloy Primer
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: V‐Primer
Number of subjects: 40
Study: 19997977

Group type: EXPERIMENTAL
Intervention: Atilmotin 150 microg IV
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Atilmotin 30 microg IV
Number of subjects: 10

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 10
Study: 17973974

Group type: EXPERIMENTAL
Intervention: Dextofisopam 200 mg b.d. for 12 weeks
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 140
Study: 17120476

Group type: EXPERIMENTAL
Intervention: Human albumin administration
Number of subjects: 8452

Group type: COMPARATOR
Intervention: Control (saline or no albumin/PPF)
Number of subjects: 8452
Study: 12832248

Group type: EXPERIMENTAL
Intervention: Individual plus group drug counseling
Number of subjects: 449

Group type: COMPARATOR
Intervention: Other psychosocial treatments (not specified)
Number of subjects: 449
Study: 10671818

Group type: EXPERIMENTAL
Intervention: Patients with imminent preterm labour
Number of subjects: 14

Group type: COMPARATOR
Intervention: Healthy women with uncomplicated pregnancies
Number of subjects: 14
Study: 8890876

Group type: EXPERIMENTAL
Intervention: Community diabetes educator presentation, video presentation, and a 4 month exercise programme
Number of subjects: 207

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 207
Study: 2060439

Group type: EXPERIMENTAL
Intervention: Metformin (1 g three times daily)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 60
Study: 6650766

Group type: EXPERIMENTAL
Intervention: 0.3 mg/kg of furosemide as a bolus injection at time 0 and again 6 hours later
Number of subjects: 18

Group type: COMPARATOR
Intervention: 0.05 mg/kg per hour of furosemide as a constant infusion for 12 hours
Number of subjects: 18
Study: 31276712

Group type: EXPERIMENTAL
Intervention: Time spent looking at food during delay of gratification task
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Time spent looking away from food during delay of gratification task
Number of subjects: 40
Study: 29561866

Group type: EXPERIMENTAL
Intervention: Preoperative vaccination against S. aureus
Number of subjects: 7647

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 7647
Study: 26762988

Group type: EXPERIMENTAL
Intervention: BMS-986001 100 mg once a day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: BMS-986001 200 mg once a day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: BMS-986001 400 mg once a day
Number of subjects: 301

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate 300 mg once a day
Number of subjects: 301

Group type: EXPERIMENTAL
Intervention: BMS-986001
Number of subjects: 301

Group type: COMPARATOR
Intervention: Tenofovir disoproxil fumarate
Number of subjects: 301
Study: 23942319

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.2-3.0 mg
Number of subjects: 564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 564

Group type: COMPARATOR
Intervention: Orlistat 120 mg × 3 per day
Number of subjects: 564
Study: 22978588

Group type: EXPERIMENTAL
Intervention: Herbal extract (HEX) at 50 mg/kg diet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monensin (MON) at 100 mg/kg diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Herbal extract (HEX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monensin (MON)
Number of subjects: 0
Study: 20332221

Group type: EXPERIMENTAL
Intervention: RUTF (Plumpy'Nut®, 1000 kcal day(‐1))
Number of subjects: 451

Group type: COMPARATOR
Intervention: CSB pre-mix (1231 kcal day(‐1))
Number of subjects: 451

Group type: EXPERIMENTAL
Intervention: RUTF
Number of subjects: 451

Group type: COMPARATOR
Intervention: CSB pre-mix
Number of subjects: 451
Study: 17006376

Group type: EXPERIMENTAL
Intervention: Soy isoflavone protein plus soy lecithin (25 g/day + 20 g/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Soy isoflavone protein (25 g/day)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Soy lecithin (20 g/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Soy isoflavone protein plus soy lecithin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Soy isoflavone protein plus placebo lecithin
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo protein plus soy lecithin
Number of subjects: 25
Study: 16282001

Group type: EXPERIMENTAL
Intervention: Educational intervention for GPs in the assessment and management of depression
Number of subjects: 30
Study: 11980758

Group type: EXPERIMENTAL
Intervention: Assisted hatching using a non-contact 1.48 mm wavelength diode laser; study group (n = 52)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Non-hatching group (n = 44)
Number of subjects: 77
Study: 10789186

Group type: EXPERIMENTAL
Intervention: IL-3
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: CYFRA 21-1
Number of subjects: 54
Study: 9139527

Group type: EXPERIMENTAL
Intervention: Pefloxacin (800 mg as single dose)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Ciprofloxacin (250 mg/8 h/72 h)
Number of subjects: 100
Study: 1871323

Group type: EXPERIMENTAL
Intervention: Immediate release formulation (MPH-IR) with a regular dose of 10mg (n=5) and 5mg (n=1) of methylphenidate (MPH) in the first pilot study.
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Slow release formulation (MPH-SR) with a regular dose of 20mg of methylphenidate (MPH) in the second pilot study.
Number of subjects: 12
Study: 6384510

Group type: EXPERIMENTAL
Intervention: Oxprenolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (group therapy only)
Number of subjects: 0
Study: 30978439

Group type: EXPERIMENTAL
Intervention: Modified protocol for hand-mixed GIC Fissure Sealants (FS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original protocol for hand-mixed GIC Fissure Sealants (FS)
Number of subjects: 0
Study: 30165479

Group type: EXPERIMENTAL
Intervention: Ablation + CRT
Number of subjects: 102

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 102
Study: 27357094

Group type: EXPERIMENTAL
Intervention: Personalized nutrition advice (level 1, level 2, level 3)
Number of subjects: 1607

Group type: EXPERIMENTAL
Intervention: Personalized nutrition advice (level 3)
Number of subjects: 1607

Group type: COMPARATOR
Intervention: Conventional dietary advice (control; level 0)
Number of subjects: 1607
Study: 25038486

Group type: EXPERIMENTAL
Intervention: Asunaprevir 200mg plus PegIFNα/RBV
Number of subjects: 238

Group type: COMPARATOR
Intervention: Placebo plus PegIFNα/RBV
Number of subjects: 238
Study: 22859321

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate treatment protocol for acute severe asthma exacerbation
Number of subjects: 143

Group type: COMPARATOR
Intervention: Standard protocol for the initial treatment of acute asthma exacerbation (Control group)
Number of subjects: 143
Study: 20301114

Group type: EXPERIMENTAL
Intervention: Chemotherapy (cisplatin/fluorouracil plus either docetaxel or epirubicin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chemotherapy (general)
Number of subjects: 0
Study: 18358671

Group type: EXPERIMENTAL
Intervention: Complete resection of the great saphenous vein stump with endothelial inversion (Group B)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Conventional flush ligation at the level of the saphenofemoral junction (Group A)
Number of subjects: 135
Study: 16011771

Group type: EXPERIMENTAL
Intervention: High-frequency electrical pulses (two pulses for subgroups 1A and 2A; four pulses for subgroups 1B and 2B)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High-frequency electrical pulses (four pulses for subgroups 1B and 2B)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Control group (15 teeth) prepared with Hero Shapers and irrigated with 5 mL of EDTA (10%) and 5 mL of 5% NaOCl at 50 degrees C, no electrical pulse treatment
Number of subjects: 75
Study: 12452757

Group type: EXPERIMENTAL
Intervention: Proton-pump inhibitors (PPIs)
Number of subjects: 0

Group type: COMPARATOR
Intervention: H2RAs or sucralfate
Number of subjects: 0
Study: 10102549

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration (GTR) using a bioabsorbable membrane
Number of subjects: 14

Group type: COMPARATOR
Intervention: Subepithelial connective tissue graft (CTG)
Number of subjects: 14
Study: 10158027

Group type: EXPERIMENTAL
Intervention: Intervention condition (theory-based intervention strategies)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Comparison condition
Number of subjects: 128
Study: 2358942

Group type: EXPERIMENTAL
Intervention: Naproxen sodium, 550 mg administered 30 minutes postoperatively
Number of subjects: 36

Group type: COMPARATOR
Intervention: Naproxen sodium, 550 mg administered 30 minutes preoperatively
Number of subjects: 36
Study: 582768

Group type: EXPERIMENTAL
Intervention: Suloctidil (Sulocton)
Number of subjects: 0
Study: 31992669

Group type: EXPERIMENTAL
Intervention: High-Flow Nasal Cannula (HFNC)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Large-Volume Nebulization-Based Humidifier
Number of subjects: 69